Related Experiment Video
Updated: May 26, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Reciprocal repression between P53 and TCTP
Robert Amson1, Salvatore Pece, Alexandra Lespagnol
1Centre National de la Recherche Scientifique-Unité Mixte de Recherche 8113, Laboratoire de Biotechnologie et Pharmacologie génétique Appliquée, École Normale Supérieure, Cachan, France.
Abstract:
Screening for genes that reprogram cancer cells for the tumor reversion switch identified TCTP (encoding translationally controlled tumor protein) as a crucial regulator of apoptosis. Here we report a negative feedback loop between P53 and TCTP. TCTP promotes P53 degradation by competing with NUMB for binding to P53-MDM2-containing complexes. TCTP inhibits MDM2 auto-ubiquitination and promotes MDM2-mediated ubiquitination and degradation of P53. Notably, Tctp haploinsufficient mice are sensitized to P53-dependent apoptosis. In addition, P53 directly represses TCTP transcription. In 508 breast cancers, high-TCTP status associates with poorly differentiated, aggressive G3-grade tumors, predicting poor prognosis (P < 0.0005). Tctp knockdown in primary mammary tumor cells from ErbB2 transgenic mice results in increased P53 expression and a decreased number of stem-like cancer cells. The pharmacological compounds sertraline and thioridazine increase the amount of P53 by neutralizing TCTP's action on the MDM2-P53 axis. This study links TCTP and P53 in a previously unidentified regulatory circuitry that may underlie the relevance of TCTP in cancer.
Insights
Translationally controlled tumor protein (TCTP) promotes cancer cell survival by degrading P53. Inhibiting TCTP restores P53 levels, sensitizes tumors to apoptosis, and may offer new cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Translationally controlled tumor protein (TCTP) is implicated in cancer progression.
- The tumor suppressor P53 plays a critical role in apoptosis and tumor suppression.
- A regulatory relationship between TCTP and P53 has not been previously defined.
Purpose of the Study:
- To elucidate the regulatory interaction between TCTP and P53.
- To investigate the role of this interaction in cancer cell biology and prognosis.
- To explore potential therapeutic strategies targeting the TCTP-P53 axis.
Main Methods:
- Investigated the interaction between TCTP and P53 using biochemical assays.
- Utilized Tctp haploinsufficient mouse models to study P53-dependent apoptosis.
- Analyzed TCTP and P53 expression in human breast cancer samples.
- Assessed the effect of Tctp knockdown in cancer cells.
- Examined the impact of pharmacological compounds on the TCTP-P53 pathway.
Main Results:
- Identified a negative feedback loop where TCTP promotes P53 degradation via the MDM2 complex.
- P53 was found to directly repress TCTP transcription.
- High TCTP levels in breast cancer correlate with aggressive G3 tumors and poor prognosis.
- Tctp knockdown increased P53 expression and reduced stem-like cancer cells.
- Sertraline and thioridazine were shown to increase P53 levels by targeting TCTP.
Conclusions:
- Established a novel regulatory circuit between TCTP and P53, impacting apoptosis and tumor suppression.
- TCTP's role in promoting P53 degradation highlights its significance in aggressive cancers.
- Targeting TCTP offers a potential therapeutic avenue for enhancing P53 function and treating cancer.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Repressible Operon: trp Operon

